More articles about NASDAQ:AMRN | Wall St. Cheat Sheet

April 08, 2013

Will Amarin’s Positive Test Result Impress These Top Institutional Shareholders?

Amarin plc's Top Institutional Shareholders for Q1 2013.

March 22, 2013

Jim Cramer: Buy Cisco and These 3 Stocks, Sell Amarin Corp

It's always a good strategy to track transparency of pundits...

March 20, 2013

Wait and Watch Palo Alto Networks and 4 More Analyst Notes to Read Now

Take a closer look at the new ratings and price targets...

February 13, 2013

4 Healthcare Stock Stories for Mid-Week Wellness

Analysis of Top healthcare Business News: 4 Healthcare Stock Stories for Mid-Week Wellness

January 05, 2013

Is Amarin a Stock to Watch in 2013?

Outperforming the broader market in 2012, healthcare stocks as group did well in 2012, but what is in store for the sector this upcoming year...

January 03, 2013

Amarin Asks FDA Okay for BASF as Supplier, NuPathe’s Notice of Allowance: Healthcare Business Recap

Your Cheat Sheet to the top healthcare business news...

December 22, 2012

Intercept Finishes POISE Enrollment, Amarin Submits NDA: Healthcare Business Report

Your Cheat Sheet to the top healthcare business news...

December 11, 2012

Apple Patent In Jeopardy and 4 Hot Stocks Round Out Tuesday

Here's the top trending stocks of the day...

December 09, 2012

Williams-Sonoma Expects Continued Growth and 4 Stock Analyses Making Rounds

Here's what analysts had to say about these companies today...

December 07, 2012

Why Did Amarin’s Financing Announcement Spark a Sell-Off?

While investors had expected Amarin to put itself up for sale or find a partner to market its cholesterol-lowering drug Vascepa, the company announced on Friday that it had raised $100 million in financing and begun hiring a sales force for the medicine...

November 29, 2012